106
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

, &
Pages 3059-3063 | Published online: 24 May 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Stig E. Andersen, Ida B. Andersen, Benny V. Jensen, Per Pfeiffer, Takayo Ota & Jim S. Larsen. (2019) A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer. Acta Oncologica 58:8, pages 1149-1157.
Read now

Articles from other publishers (8)

Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat & Anna Forsythe. (2023) Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future Oncology.
Crossref
Heather Poad, Sam Khan, Lorna Wheaton, Anne Thomas, Michael Sweeting & Sylwia Bujkiewicz. (2022) The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status. Cancers 14:21, pages 5391.
Crossref
Yuki Nakagawa, Takuya Yoshimoto, Shintaro Nakagawa, Yasuo Sugitani, Hideharu Yamamoto & Takashi Asakawa. (2021) Impact of Tumor Assessment Frequency on Statistical Power in Randomized Cancer Clinical Trials Evaluating Progression-Free Survival. Therapeutic Innovation & Regulatory Science 55:6, pages 1258-1264.
Crossref
Pilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, Paula Jiménez-Fonseca, Carles Pericay, Federico Longo-Muñoz, Carmen Reyna-Fortes, Guillem Argilés-Martínez, Beatriz González-Astorga, María José Gómez-Reina, Ana Ruiz-Casado, Nuria Rodríguez-Salas, Rafael López-López, Alberto Carmona-Bayonas, Verónica Conde-Herrero & Enrique Aranda. (2021) Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study. Cancers 13:18, pages 4514.
Crossref
Yaowen Zhang, Junhui Gao, Anping Zheng, Haijun Yang, Jian Li, Shouxin Wu, Jiangman Zhao, Peng Meng & Fuyou Zhou. (2021) Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection. Translational Oncology 14:6, pages 101066.
Crossref
L. Mineur, E. François, C. Plassot, J. M. Phelip, L. Miglianico, L. M. Dourthe, N. Bonichon, L. Moreau, R. Guimbaud, D. Smith, E. Achille, R. Hervé, J. M. Bons, S. Remy, R. Faroux, A. L. Villing, A. Mahamat, I. Rabbia, P. Soulié, I. Baumgaertner, N. Mathé, L. Vazquez & R. Boustany. (2020) PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer. PLOS ONE 15:12, pages e0243997.
Crossref
Y. Yao, R. Deng, D. Liao, H. Xie, J. Zuo, Y. Jia & F. Kong. (2020) Maintenance treatment in advanced HER2-negative gastric cancer. Clinical and Translational Oncology 22:12, pages 2206-2212.
Crossref
Tung Hoang & Jeongseon Kim. (2020) Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers 12:9, pages 2663.
Crossref